Review Article
Pediatric Sclerosing Rhabdomyosarcomas: A Review
Table 2
Histopathological, immunohistochemical, and genetic features of 21 cases of pediatric sclerosing rhabdomyosarcomas.
| | Year | Author | Age/
Sex | Vimentin | Desmin | Myogenin (myf4) | MyoD1 | SMA | Cytokeratin | S100 | CD99 | Amount of fibrosis | Rhabdo-myoblasts | Mitoses | PAX3/FXHR by RT-PCR | Karyotype |
| | 2002 | Folpe et al. [8] | 18/M | NA | Focally (+) | Focally (+) | Strongly (+) | 3+ | Neg. | Neg. | Neg. | Abundant | (−) | >25/20 HPF | NA | NA |
| | 2004 | Vadgama et al. [9] | 3/F | Strongly (+) | Strongly (+) | Focally (+) | Strongly (+) | Focally (+) | Neg. | Neg. | Focally (+) | Dense | (−) | 32/100 HPF | Neg. | NA |
| | 2004 | Chiles et al. [7] | 6/M | NA | Pos. | Pos. | Pos. | NA | NA | NA | NA | >50% | (−) | NA | NA | NA | | 11/M | NA | NA | NA | NA | NA | NA | NA | NA | 10–50% | (−) | NA | Neg. | CK | | 7/F | NA | Focally (+) | Focally (+) | Strongly (+) | NA | NA | NA | NA | >50% | (−) | NA | NA | NA | | 10/F | NA | Strongly (+) | Focally (+) | Strongly (+) | NA | NA | NA | NA | >50% | (−) | NA | Neg. | NA | | 3/M | NA | Strongly (+) | Focally (+) | Strongly (+) | NA | NA | NA | NA | >50% | (−) | NA | Pos. | NA | | 8/F | NA | Strongly (+) | Focally (+) | Strongly (+) | NA | NA | NA | NA | >50% | (−) | NA | NA | NA | | 16/F | NA | Focally (+) | Focally (+) | Strongly (+) | NA | NA | NA | NA | >50% | (−) | NA | Neg. | NA | | 4/F | NA | Strongly (+) | Strongly (+) | Strongly (+) | NA | NA | NA | NA | 10–50% | (−) | NA | NA | NA | | 12/M | NA | Strongly (+) | Focally (+) | Strongly (+) | NA | NA | NA | NA | >50% | (−) | NA | Neg. | NA | | 9/M | NA | Focally (+) | Strongly (+) | Strongly (+) | NA | NA | NA | NA | 10–50% | (−) | NA | NA | CK | | 4/M | NA | Strongly (+) | Strongly (+) | Strongly (+) | NA | NA | NA | NA | 10–50% | (−) | NA | NA | NA | | 0.3/M | NA | Focally (+) | Strongly (+) | Strongly (+) | NA | NA | NA | NA | 10–50% | (−) | NA | NA | NA | | 5/M | NA | Strongly (+) | Focally (+) | Focally (+) | NA | NA | NA | NA | >50% | (+) | NA | Neg. | NA |
| |
2006 |
Zambrano et al. [11] | 8/F | NA | Strongly (+) | Focal (+) | Focally (+) | Focally (+) | NA | Neg. | Neg. | Abundant | (−) | Numerous | Neg. | NK | | 18/M | NA | Strongly (+) | Weakly (+) | Strongly (+) | Strongly (+) | NA | Neg. | Weakly (+) | Abundant | (−) | Numerous | Neg. | CK | | 17/F | NA | Focally (+) | Focally (+) | Focally (+) | Focally (+) | NA | Neg. | Weakly (+) | Abundant | (+) | Numerous | Neg. | CK |
| | 2008 | Wang et al. [10] | 12/F | Strongly (+) | Focally (+) | Focally (+) | Strongly (+) | Focally (+) | NA | Pos. | NA | Abundant | (−) | 5/10 HPF | NA | NA |
| | 2009 | Bouron-Dal Soglio et al. [6] | 7/M | NA | Strongly (+) | Focally (+) | NA | NA | NA | NA | NA | Abundant | (−) | NA | Neg. | CK |
| | 2013 | Present case | 11/M | Strongly (+) | Strongly (+) | Focal (+) | Not done | Neg. | Neg. | Neg. | Neg. | Abundant | (−) | NA | Not done | Not done |
|
|
NA: not available; Neg.: negative; Pos.: positive; HPF: high power field; CK: complex karyotype; NK: normal karyotype.
|
